🔗 Share this article

While America continues making unprecedented changes to its vaccine recommendations, one figure appears in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by casting doubt on coronavirus vaccinations throughout the pandemic and has zeroed in on potential deaths following COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Program

Public health authorities planned to reveal major changes to the childhood vaccine schedule in December, aligning the US with the Danish immunization schedule, it is understood – a major change that would put the US out of step with much of the world with insufficient data for benefit. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to run the division this calendar year.

Consolidating Power at the Agency

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending some pediatric shot schedules in the US in order to be more in line with Denmark, a country with nationalized medicine and a population approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious track record in drug development, approval processes or management, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Former heads of CBER would “understand regulatory frameworks and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who headed CBER have had.”

This division has an enormous workload at the agency, the former commissioner emphasized.

“Many people just pays attention on the new drug program, but the generic drug division approves thousands of generic drugs. There’s a biosimilars program, OTC medication office and more, and each of these must be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management aspect to the job, which manages in excess of 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” Woodcock added.

Response and Controversial Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this assignment indicates more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries rely on incorrect assumptions”.

“This background matches the duties of her role,” the representative said, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s new expedited review system, a disputed one-day medication authorization process that apparently troubled her predecessors. “By what process are these medications being selected for this fast-track system? Who takes the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he stated, “the agency seems to be moving towards less stringent rules of pharmaceuticals, except for immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if concerning, past, Howard have noted. She authored a analysis using unverified volunteer-provided data to assess the rate of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the new government encompassed revising rules for recently developed shots and ending “optional” immunizations, she said after the election on a online show. At the FDA, Høeg has according to sources proposed preventing adolescent males from getting COVID-19 vaccinations.

“She is an thorough true believer who starts off with her preconceived notions and tailors the evidence to retrofit the data in a very misleading, fraudulent fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|